104163-34-0

Basic information

• Product Name: 5-methyl-2-Thiophenemethanamine
• Synonyms: 1-(5-methyl-2-thienyl)methanamine(SALTDATA: FREE);[(5-Methyl-2-thienyl)methyl]amine hydrochloride;(5-Methylthiophen-2-yl)MethanaMine;2-ThiopheneMethanaMine,5-Methyl-;1-(5-METHYL-2-THIENYL)METHANAMINE;(5-Methylthiophen-2-yl)
• CAS NO: 104163-34-0
• Molecular Formula: C₆H₉NS
• Molecular Weight: 127.21
• Product Categories: Thiophens
• Mol File: 104163-34-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 198.8°C at 760 mmHg
• Flash Point: 74°C
• Appearance: /
• Density: 1.104g/cm³
• Vapor Pressure: 0.353mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.98±0.29(Predicted)
• CAS DataBase Reference: 5-methyl-2-Thiophenemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-2-Thiophenemethanamine(104163-34-0)
• EPA Substance Registry System: 5-methyl-2-Thiophenemethanamine(104163-34-0)

Safety Data

• Statements: 34
• Safety Statements: 26-27-36/37/39-45
• RIDADR: 3267
• HazardClass: IRRITANT
• Hazardous Substances Data: 104163-34-0(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C6H9NS/c1-5-2-3-6(4-7)8-5/h2-3H,4,7H2,1H3

Upstream product

• 554-14-3 2-Methylthiophene 
• 42456-40-6 5-methyl-2-thiophenecarbaldehyde oxime 
• 13679-70-4 5-methylthiophene-2-carboxaldehyde 
• 765-58-2 2-bromo-5-methyl thiophene 
• 72835-25-7 2-cyano-5-methylthiophene 

Downstream Products

• 721958-87-8 2-[(5-methyl-thiophen-2-ylmethyl)-amino]-ethanol 
• 90765-35-8 5-Methyl-thenyl-(2)-3-hydroxy-propylamin 
• 171661-55-5 (5-methylthien-2-yl)methylamine hydrochloride 
• 1018480-82-4 C₁₈H₁₆F₃N₃O₂S₂ 
• 1035346-69-0 4-((diphenylmethyleneamino)methyl)-N-((5-methylthiophen-2-yl)methyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1105691-16-4 2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-4-methyl-N-((5-methylthiophen-2-yl)methyl)thiazole-5-carboxamide 

Relevant articles and documents

Convenient one-pot methodology for the primary aminomethylation of electron rich heterocycles

Primary aminomethyl groups were introduced into the 2-position of electron rich heterocycles in moderate to good yields by a one-pot sequence involving lithiation, transmetalation into an organozinc reagent and treatment with 1-(triphenylphosphoroylideneaminomethyl)benzotriazole (betmip).

Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold

Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the heat shock protein 90 kDa (Hsp90) family of molecular chaperones. Grp94 associates with many proteins involved in cell adhesion and signaling, including integrins, Toll-like receptors, immunoglobulins, and mutant myocilin. Grp94 has been implicated as a target for several therapeutic areas including glaucoma, cancer metastasis, and multiple myeloma. While 85% identical to other Hsp90 isoforms, the N-terminal ATP-binding site of Grp94 possesses a unique hydrophobic pocket that was used to design isoform-selective inhibitors. Incorporation of a cis-amide bioisostere into the radamide scaffold led to development of the original Grp94-selective inhibitor, BnIm. Structure-activity relationship studies have now been performed on the aryl side chain of BnIm, which resulted in improved analogues that exhibit better potency and selectivity for Grp94. These analogues also manifest superior antimigratory activity in a metastasis model as well as enhanced mutant myocilin degradation in a glaucoma model compared to BnIm.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT